The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 14, Issue 1, 1999, Pages 3-47

  Cacabelos, RamóN ^a   Takeda, Masatoshi ^b   Winblad, Bengt ^c  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 7 TRIFLUOROMETHYL 2,3 QUINOXALINEDIONE; ALLOPURINOL; AMANTADINE; AMINO ACID RECEPTOR AFFECTING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR ANTAGONIST; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BUDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CATECHOLAMINE; CYTOSKELETON PROTEIN; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GROWTH FACTOR; IPENOXAZONE; LAMOTRIGINE; LIFARIZINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROSTEROID; PENTOSTATIN; RILUZOLE; SIPATRIGINE; SODIUM CHANNEL BLOCKING AGENT;

ADULT; ALZHEIMER DISEASE; APOPTOSIS; CHROMOSOME MAP; DRUG DEVELOPMENT; GENE CONTROL; GENETIC PREDISPOSITION; GENETIC SCREENING; HEALTH CARE COST; HUMAN; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; RAT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENILE PLAQUE;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BRAIN; HUMANS; RECEPTORS, GLUTAMATE; RISK ASSESSMENT;

EID: 0032950029     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO;2-7     Document Type: Review

References (228)

1. Agüero Torres, H. (1998) Natural history of Alzheimer's disease and other dementias - findings from a population based study. PhD Thesis, Karolinska Institute, Stockholm.
2. Agüero Torres, H., Fratiglioni, L., Guo, Z., Viitanen, M., von Strauss, E. and Winblad, B. (1998) Dementia is the major cause of functional dependence in the elderly. Three-year follow-up data from a population based study. Am. J. Pub. Health (in press).
3. Araque, A., Parpura, V., Sanzgiri, R. P. and Haydon, P. G. (1998) Glutamate-dependent astrocyte modulation of synaptic transmission between cultured hippocampal neurons. Eur. J. Neurosci. 10, 2129-2142.
4. Auld, D. S., Kar, S. and Quirion, R. (1998) β-Amyloid peptides as direct cholinergic neuromodulators: A missing link? Trends Neurosci. 21, 43-49.
5. Baltrons, M. A. and Garcia, A. (1997) AMPA receptors are coupled to nitric oxide/cyclic GMP pathway in cerebellar astroglial cells. Eur. J. Neurosci. 9, 2497-2501.
6. Barnard, E. A. (1997) Ionotropic glutamate receptors: New types and new concepts? Trends Pharmacol. Sci. 18, 141-148.
7. Barnes, C. A., Danysz, W. and Parsons, C. G. (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term polentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur. J. Neurosci. 8, 565-571.
8. Barria, A., Muller, D., Derkrach, V., Griffith, L. C. and Soderling, T. R. (1997) Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. Science 276, 2042-2044.
9. Bekkers, J. M. and Stevens, C. F. (1989) NMDA and non-NMDA receptors are co-localized at individual excitatory synapses in cultured rat hippocampus. Nature 341, 230-233.
10. Beyer, K., Lao, J. I. and Cacabelos, R. (1996a) Molecular genetics and genotyping in Alzheimer's disease. Ann. Psychiat. 6, 173-187.
11. Beyer, K. Lao, J. I. Alvarez, X. A. and Cacabelos, R. (1996b) Different implications of APOE-4 in Alzheimer disease and vascular dementia in the Spanish population. Alz. Rex. 2, 215-220.
12. Beyer, K., Lao, J. I., Fernández-Novoa, L. and Cacabelos, R. (1998) Identification of a novel mutation (V148I) in the TM2 domain of the presenilin 2 gene in a patient with late-onset Alzheimer disease. Neurobiol. Aging 19/4S, S87.
13. Bezard, E., Bioulac, B. and Gross, C. E. (1988) Glutamatergic compensatory mechanisms in experimental parkinsonism. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 22, 609-623.
14. Bezzi, P., Carmignoto, G., Pasti, L. et al. (1998) Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 391, 281-285.
15. Biggs, C. S. and Starr, M. S. (1997) Dopamine and glutamate control each other's release in the basal ganglia: A microdialysis study of the entopeduncular nucleus and substantia nigra. Neurosci. Biobehav. Rev. 21, 497-504.
16. Bliss, T. V. P. and Lomo, T. (1973) Long-lasting potentiation of synaptic transmission in the dentate gyrus of the unanesthetized rabbit following stimulation of the perforant path. J. Physiol. (Lond). 232, 357-374.
17. Brakeman, P. R., Lanahan, A. A., O'Brien, R. et al. (1997) Homer: A protein that selectively binds metabotropic glutamate receptors. Nature 386, 284-288.
18. Brann, D. W. and Mahesh, V. B. (1992) Excitatory amino acid neurotransmission. Evidence for a role in neuroendocrine regulation. TEM 3, 122-126.
19. Bravin, M., Savio, T., Strata, P. and Rossi, F. (1997) Olivocerebellar axon regeneration and target reinnervation following dissociated Schwann cell grafts in surgically injured cerebella of adult rats. Eur. J. Neurosci. 9, 2634-2649.
20. Brayne, C., Best, N., Muir, M., Richards, S.-J. and Gill, C. (1997) Five-year incidence and prediction of dementia and cognitive decline in a population sample of women aged 70-79 at baseline. Int. J. Geriatr. Psychiat. 12, 1107-1118.
21. Breukel, A. I. M., Besselsen, E., Lopes da Silva, F. H. and Ghijsen, W. E. J. M. (1998) A presynaptic N-methyl-D-aspartate autoreceptor in rat hippocampus modulating amino acid release from a cytoplasmic pool. Eur. J. Neurosci. 10, 106-114.
22. Budziszewska, B., Siwanowicz, J., Leskiewicz, M., Jaworska-Feil, L. and Lason, W. (1998) Protective effects of neurosteroids against NMDA-induced seizures and lethality in mice. Eur. Neuropsychopharmacol. 8, 7-12.
23. Butterfield, D. A., Hensley, K., Cole, P. et al. (1997) Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: Relevance to Alzheimer's disease. J. Neurochem. 68, 2451-2457.
24. Cacabelos, R. (1994) New strategies for Alzheimer's disease treatment: Pleiotropic drugs and multifactorial intervention. In Alzheimer Disease: Therapeutic Strategies (E. Giacobini and R. Becker, Eds). Birkhäuser, Boston, pp. 493-498.
25. Cacabelos, R. (1995a) Senile dementia. In Enciclopedia Iberoamericana de Psiquiatría. (G. Vidal, R. D. Alarcón and F. L. Stepke, Eds). Editorial Médica Panamericana, Buenos Aires, pp. 359-386.
26. Cacabelos, R. (1995b) Tacrine: First generation of antidementia drugs. Med. Clin. 105, 105-115.
27. Cacabelos, R. (1996) Diagnosis of Alzheimer's disease: Defining genetic profiles (genotype vs phenotype). Acta Neurol. Scand., Suppl., 165, 72-84.
28. Cacabelos, R. (1997a) Dementia. In Clinical Neuropsychiatry (T. H. Jobe, M. Gavira and A. Kovilparambil, Eds). Blackwell Science, Massachusetts, pp. 73-122.
29. Cacabelos, R. (1997b) Alzheimer disease. Rev. Med. Pract. Clin. 2, 124-142.
30. Cacabelos, R. (1998) Alzheimer Disease. Aging and Dementia. Masson, Barcelona, (in press).
31. Cacabelos, R., Alvarez, X. A., Fernández-Novoa, L. et al. (1994a) Brain interleukin-1β in Alzheimer's disease and vascular dementia. Meth. Find. Exp. Clin. Pharmacol. 16, 141-151.
32. Cacabelos, R., Alvarez, X. A., Franco-Maside, A., Fernández-Novoa, L. and Caamaño, J. (1994b) Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. Meth. Find. Exp. Clin. Pharmacol. 16, 29-35.
33. Cacabelos, R., Nordberg, A., Caamaño, J. et al. (1994c) Molecular strategies for the first generations of antidementia drugs (I). Tacrine and related compounds. Drugs Today 30, 295-337.
34. Cacabelos, R., Nordberg, A., Caaman̈o, J. et al. (1994d) Therapeutic strategies in Alzheimer's disease. Ann. Psychiat. 4, 221-279.
35. Cacabelos, R., Lao, J. I., Beyer, K., Alvarez, X. A. and Franco-Maside, A. (1996) Genetic testing in Alzheimer's disease: APOE genotyping and etiopathogenic factors. Meth. Find. Exp. Clin. Pharmacol. 18, Suppl. A, 161-178.
36. Cacabelos, R., Rodríguez, B., Carrera, C., Beyer, K., Lao, J. I. and Sellers, M. A. (1997) Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alz. Dis. Assoc. Disord. 11 (Suppl. 4), S27-S34.
37. Cacabelos, R., Pérez del Tío, L. and Sellers, A. (1998a) Caregivers perception on dementia-associated social, economic and health problems: Sociodemographic study in the Spanish population. Jap. J. Geriat. Psychiat. 9, 133-139.
38. Cacabelos, R., Winblad, B. and Eikelenboom, P. (Eds) (1998b) Inflammation and Neuroimmunotrophic Activity in Alzheimer's Disease. Neurogerontology and Neurogeriatrics, Vol. 2. Prous Science, Barcelona.
39. Cacabelos, R., Lao, J. I., Beyer, K., Laredo, M., Pichel, V., Sellers, M. A., Pérez, P. and Alvarez, X. A. (1998c) Genotype-specific therapeutic response in Alzheimer disease patients treated with a multifactorial strategy. Meth. Find. Exp. Clin. Pharmacol. (in press).
40. Cacabelos, R., Beyer, K., Lao, J. I., Mesa, M. D. and Fernández-Novoa, L. (1998d) Association of genetic risk factors and a novel mutation in the predicted TM2 domain of the presenilin 2 gene in late-onset AD. In Alzheimer's Disease and Related Disoders. (K. Igbal, D. F. Swaab, B. Winblad, H. M. Wizniewski, Eds). Wiley, Chichester, (in press).
41. Cain, D. P. (1998) Testing the NMDA, long-term potentiation, and cholinergic hypothesis of spatial learning. Neurosci. Biobehav. Rev. 22, 181-193.
42. 2+ responses linked to metabotropic and ionotropic glutamate receptors in rat hippocampal slices. Eur. J. Neurosci. 9, 1625-1635.
43. Castellino, A. (1997) A systems perspective begins to emerge in Alzheimer's. Nature Biotechnol. 15, 1347-1348.
44. Cavallo, M. C. and Fattore, G. (1997) The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy. Alz. Dis. Assoc. Disord. 11, 184-190.
45. Choi, D. W. (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1, 623-634.
46. Copani, A., Casabona, G., Bruno, V. et al. (1998) The metabotropic glutamate receptor mGlu5 controls the onset of developmental apoptosis in cultured cerebellar neurons. Eur. J. Neurosci. 10, 2173-2184.
47. Corder, E. H., Saunders, A. M., Strittmatter, W. J. et al. (1993) Gene dose of a polipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
48. Corder, E. H., Saunders, A. M., Risch, N. J. et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet. 7, 180-183.
49. Cotman, C. W., Monaghan, D. T., Offersen, O. P. and Storm-Mathisen, J. (1987) Anatomical organization of EAA receptors and their pathways. Trends Neurosci. 10, 273-280.
50. Cotman, C. W., Khale, J. S., Miller, S. E., Ulas, J. and Bridges, R. J. (1995) Excitatory amino acid neurotransmission. In Psychopharmacology: The Fourth Generation of Progress. (F. E. Bloom and D. J. Kupfer, Eds). Raven Press, New York, pp. 75-85.
51. Couratier, P., Lesort, M., Terro, F., Dussartre, C. and Hugon, J. (1996) NMDA antagonist blockade of AT8 tau immunoreactive changes in neuronal cultures. Fund. Clin. Pharmacol. 10, 344-349.
52. Cozzi, A., Attucci, S., Peruginelli, F., Marinozzi, M., Luneia, R., Pellicciari, R. and Moroni, P. (1997) Type 2 metabotropic glutamate (mGlu) receptors tonically inhibit transmitter release in rat caudate nucleus: In vivo studies with (2S,1′S,2′S,3′R)-2-(2′-carboxy-3'-phenylcyclopropyl) glycine, a new potent and selective antagonist. Eur. J. Neurosci. 9, 1350-1355.
53. Criton, M., Westaway, D., Xia, W. et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nature Med. 3, 67-72.
54. Danysz, W., Parsons, C. G., Bresink, I. and Quack, G. (1995) Glutamate in CNS disorders. Drugs News Perspect. 8, 261-277.
55. Danysz, W., Parsons, C. G., Kornhuber, J., Schmidt, W. J. and Quack, G. (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies. Neurosci. Biobehav. Rev. 21, 455-468.
56. Dawson, V. L., Dawson, T. M., London, D. E., Bredt, D. S. and Snyder, S. H. (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Nat. Acad. Sci. USA 88, 6388-6368.
57. De Boni, U. and McLachlan, D. R. (1985) Controlled induction of paired helical filaments of Alzheimer type in cultured human neurons by glutamate and aspartate. J. Neurol. Sci. 68, 105-118.
58. De la Torre, J. C. and Hachinski, V. (Eds) (1997) Cerebrovascular pathology in Alzheimer's disease. Ann. NY Acad. Sci. 826.
59. Diano, S., Naftolin, F. and Horvath, T. L. (1998) Kainate glutamate receptors (GluR5-7) in the rat arcuate nucleus: Relationship to tanycytes, astrocytes, neurons and gonadal steroid receptors. J. Neuroendocrinol. 10, 239-247.
60. Dickens, B. M. (1994) Legal issues in predictive genetic testing programs. Alz. Dis. Assoc. Disord. 8, 94-101.
61. Ditzler, K. (1991) Efficacy and tolerability of memantine in patients with dementia syndrome. Drug Res. 41, 773-780.
62. Dong, H., O'Brien, R. J., Fung, E. T., Lanahan, A. A., Worley, P. F. and Huganir, R. L. (1997) A synaptic PDZ domain-containing protein that interacts with AMPA receptors. Nature 386, 279-284.
63. Eikelenboom, P., Zhan, S. S., Van Gool, W. A. and Allsop, D. (1994) Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15, 447-450.
64. El Khoury, J., Hickman, S. E., Thomas, C. A., Cao, L., Silverstein, S. C. and Loike, J. D. (1996) Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature 382, 716-719.
65. Emanuel, E. J. and Emanuel, L. L. (1994) The economics of dying. The illusion of cost savings at the end of life. New Engl. J. Med. 330, 540-544.
66. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwmatsu, A. and Nagata, S. (1998) A caspase-activated Dnase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391, 43-50.
67. Esclaire, F., Lesort, M., Blanchard, C. and Hugon, J. (1997) Glutamate toxicity enhances tau gene expression in neuronal cultures. J. Neurosci. Res. 49, 309-318.
68. Ferrer-Montiel, A. V., Merino, J. M., Blondelle, S. E., Pérez-Payá, E., Houghten, A. and Montal, M. (1998) Selected peptides targeted to the NMDA receptor channel protect neurons from excitotoxic death. Nature Biotech. 16, 286-291.
69. Florillo, C. D. and Williams, J. T. (1998) Glutamate mediates an inhibitory postsynaptic potential in dopamine neurons. Nature 394, 78-81.
70. Fratiglioni, L. (1998) Classifications and diagnostics. In Health Economics of Dementia (B. Winblad, A. Wimo, B. Jonsson and G. Karlsson, Eds). Wiley, Chichester, pp. 3-11.
71. Fratiglioni, L., Viitanen, M., von Strauss, E., Tondonati, V., Herlitz, A. and Winblad, B. (1997a) Very old women at highest risk of dementia and Alzheimer's disease. Incidence data from the Kungsholmen Project, Stockholm. Neurology 48, 132-138.
72. Fratiglioni, L., Viitanen, M., von Strauss, E. and Winblad, B. (1997b) Late-onset Alzheimer's disease: Incidence data from the Kungsholmen Project. In Alzheimer's Disease: Biology, Diagnosis and Therapeutics (K. Iqbal, B. Winblad, T. Nishimura, M. Takeda and H. M. Wisniewski, Eds). Wiley, Chichester, pp. 49-53.
73. Gaspary, H. L. (1998) AMPA receptors: Players in calcium-mediated neuronal injury? Neuroscientist 4, 149-153.
74. Gegelashvili, G. and Schousboe, A. (1997) High affinity glutamate transporters: Regulation of expression and activity. Mol. Pharmacol. 52, 6-15.
75. Gewirtz, J. and Davis, M. (1997) Second-order fear conditioning prevented by blocking NMDA receptors in amygdala. Nature 388, 471-474.
76. Gip, C., Viitanen, M., von Straauss, E., Winblad, B. and Fratiglioni, L. (1997) Prevalence of dementia in nonagenarians. In Alzheimer's Disease: Biology, Diagnosis and Therapeutics (K. Iqbal, B. Winblad, T. Nishimura, M. Takeda and H. M. Wisniewski, Eds). Wiley, Chichester, pp. 45-48.
77. Godard, B., Knoppers, B. M., Glads K. et al. (1994) Ethical issues involved in establishing a registry for familial Alzheimer's disease. Alz. Dis. Assoc. Disord. 8, 79-93.
78. Görtelmeyer, R. and Erbler, H. (1992) Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Drug Res. 42, 904-913.
79. Görtelmeyer, R., Pantev, M., Parsons, C. G. and Quack, G. (1993) The treatment of dementia syndrome with Akatine Memantine®, a modulator of the glutamatergic system. In Spektrum der Neurorehabilitation (K. Von Wild, Ed.). W. Zuckswerdt Verlag, Munich, pp. 50-56.
80. Gracon, S., Smith, F., Hoover, T., Schneider, L., Davis, K. and Talwalker, S. (1996) Long-term tacrine treatment: Effect of nursing home placement and mortality. In Alzheimer Disease: From Molecular Biology to Therapy (R. Becker and E. Giacobini, Eds). Birkhäuser, Boston, pp. 205-209.
81. Greenamyre, J. T., Maragos, E. F., Albin, R. L., Penney, J. B. and Young, A. B. (1988) Glutamate transmission and toxicity in Alzheimer's disease. Prog. NeuroPsych. Biol. Psych. 12, 421-430.
82. 3H]glutamate binding. J. Neurochem. 48, 543-551.
83. Greenamyre, J. T., Penney, J. B., Young, A. B., D'Amato, C. J., Hicks, S. P. and Shoulson, I. (1985) Alterations in glutamate binding in Alzheimer's and Huntington's disease. Science 227, 1496-1499.
84. Greenamyre, J. T. and Young A. B. (1989) Excitatory amino acids and Alzheimer's disease. Neurobiol. Aging 10, 593-602.
85. Grima, G., Benz, B. and Do, K. Q. (1997) Glutamate-induced release of the nitric oxide precursor, arginine, from glial cells. Eur. J. Neurosci. 9, 2248-2258.
86. Hardy, J. (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154-159.
87. Hashimoto, T., Inazawa, J., Okamoto, N. et al. (1997) The whole nucleotide sequence and chromosomal localization of the gene for human metabotropic glutamate receptor subtype 6. Eur. J. Neurosci. 9, 1226-1235.
88. i increase in isolated rat supraoptic neurons. J. Neuroendocrinol. 10, 383-389.
89. Hay, J. W., Sano, M. and Whitehouse, P. (1997) The costs and social burdens of Alzheimer disease: What can and should be done? Alz. Dis. Assoc. Disord. 11, 181-183.
90. Helme-Guizon, A., Davis, S., Israel, M., Lesbats, B., Mallet, J., Laroche, S. and Hicks, A. (1998) Increase in syntaxin 1B and glutamate release in mossy fibre terminal following induction of LTP in the dentate gyrus: A candidate molecular mechanism underlying transsynaptic plasticity. Eur. J. Neurosci. 10, 2231-2237.
91. Henderson, A. S., Easteal, S., Jorm, A. F., Mackinnon, Koren, A. E., Croft, L. and Jacomb, P. A. (1995) Apolipoprotein E allele ε4, dementia, and cognitive decline in a population sample. Lancet 346, 1387-1390.
92. Henderson, V. W. (1997) Estrogen replacement therapy for the prevention and treatment of Alzheimer's disease. CNS Drugs 8, 343-351.
93. Henley, J. M. (1994) Kainate-binding proteins: Phylogeny, structures and possible functions. Trends Pharmacol. Sci. 15, 182-190.
94. Heresco-Levy, U. and Javitt, D. C. (1998) The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur. Neuropsychopharmacol. 8, 141-152.
95. Herrera-Marschitz, M., Goiny, M.,. You, Z. B. et al. (1997) On the release of glutamate and asparate in the basal ganglia of the rat: Interactions with monoamines and neuropeptides. Neurosci. Biobehav. Rev. 21, 489-495.
96. Hisama, F. M. and Schellenberg, G. D. (1996) Progress in molecular genetics of Alzheimer's disease. Neuroscientist 2, 3-6.
97. Holcomb, L., Gordon, M. N., McGowan, E. et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature 4, 97-100.
98. Inenaga, K., Cui, L. N., Nagamoto, T., Honda, E., Ueta, Y. and Yamashita, H. (1997) Osmotic modulation in glutamatergic excitatory synaptic inputs to neurons in the supraoptic nucleus of rat hypothalamus in vitro. J. Neuroendocrinol. 9, 63-68.
99. Ishii, T., Moriyoshi, K., Sugihara, H. et al. (1993) Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J. Biol. Chem. 268, 2836-2843.
100. Issa, B. G., Lewis, B. M., Ham, J., Peters, J. R. and Scanlon, M. F. (1998) Glutamate pathways mediate somatostatin responses to glucose in normal and diabetic rat hypothalamus. J. Neuroendocrinol. 10, 377-381.
101. Jenkins, R. and Hill, S. (1996) Chronic care. Long-term care in an ageing society. Financial Times. FT Pharmaceuticals & Healthcare Publishing, London.
102. Joanny, P., Steinberg, J., Olivier, C. and Grino, M. (1997) Glutamate and N-methyl-D-aspartate stimulate rat hypothalamic corticotropin-releasing factor secretion in vitro. J. Neuroendocrinol. 9, 93-97.
103. Joutel, A., Corpechot, C., Ducros, A. et al. (1997) Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia. Ann. NY Acad. Sci. 826, 213-217.
104. Kanai, Y. and Hediger, M. A. (1992) Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 360, 467-471.
105. Karlinsky, H., Sadovnick, A. D., Burgess, M. M., Langlois, S., Hayden, M. R. and Berg, J. M. (1994) Issues in molecular genetic testing of individuals with suspected early-onset familial Alzheimer's disease. Alz. Dis. Assoc. Disord. 8, 116-125.
106. Keller, J. N., Pang, Z., Geddes, J. W., Begley, J. G., Germeyer, A., Waeg, G. and Mattson, M. P. (1997) Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: Role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 69, 273-284.
107. Kentros, C., Hargreaves, E., Hawkins, R. D., Kandel, E. R., Shapiro, M. and Muller, R. V. (1998) Abolition of long-term stability of new hippocampal place cell maps by NMDA receptor blockade. Science 280, 2121-2126.
108. Khachaturian, Z. S. (1997) Plundered memories. Sciences 37, 20-25.
109. Kim, T. W., Pettingell, W. H., Jung, Y. K., Kovacs, D. M. and Tanzi, R. E. (1997) Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science 277, 373-376.
110. Kornhuber, J., Weller, M., Schoppmeyer, K. and Riederer, P. (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural Transm. 43, 91-104.
111. Kornhuber, J. and Weller, M. (1997) Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy. Biol. Psychiat. 41, 135-144.
112. Kreutzberg, G. W. (1996) Microglia: A sensor for pathological events in the CNS. Trends Neurosci. 19, 312-318.
113. Kullmann, D. M. and Asztely, F. (1998) Extrasynaptic glutamate spillover in the hippocampus: Evidence and implications. Trends Neurosci. 21, 8-14.
114. Lamb, B. T. (1997) Presenilins, amyloid-β and Alzheimer's disease. Nature Med. 3, 28-29.
115. Lancaster, B. and Rogers, M. V. (1998) A peptide activator of endogenous tyrosine kinase enhances synaptic currents mediated by NMDA receptors. Eur. J. Neurosci. 10, 2302-2308.
116. Lennox, A., Karlinsky, H., Meschino, W., Buchanan, J. A., Percy, M. E. and Berg, J. M. (1994) Molecular genetic predictive testing for Alzheimer's disease: Deliberations and preliminary recommendations. Alz. Dis. Assoc. Disord. 8, 126-147.
117. Levy-Lahad, E., Wijsman, E. M., Nemens, E. et al. (1995) A familial Alzheimer's disease locus on chromosome 1. Science 269, 970-973.
118. Li, P. and Zhuo, M. (1998) Silent glutamatergic synapses and nociception in mammalian spinal cord. Nature 393, 695-698.
119. Li, S., Mallory, M., Alford, M., Tanaka, S. and Masliah, E. (1997) Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol. 56, 901-911.
120. Lipton, S. A., Choi, Y.-B., Pan, Z.-H. et al. (1993) A redox-based mechanism for neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364, 626-632.
121. Lipton, S. A. and Rosenberg, P. A. (1994) Excitatory amino acids as a final common pathway for neurologic disorders. New Engl. J. Med. 330, 613-622.
122. Lovestone, S. (1996) The genetics of Alzheimer's disease - New opportunities and new challenges. Int. J. Geriatr. Psychiat. 11, 491-497.
123. Lynch, J. W., Kaplan, G. A. and Shema, S. J. (1997) Cumulative impact of sustained economic hardship on physical, cognitive, psychological, and social functioning. New Engl. J. Med. 337, 1889-1895.
124. Lynch, G., Kessler, M., Rogers, G., Ambros-Ingersen, J., Granger, R. and Schehr, R. S. (1996) Psychological effects of a drug that facilitates brain AMPA receptors. Int. Clin. Psychopharmacol. 11, 13-19.
125. Mahanty, N, K. and Sah, P. (1998) Calcium-permeable AMPA receptors mediate long-term potentiation in interneurons in the amygdala. Nature 394, 683-687.
126. Manzoni, O., Michel, J. M. and Bockaert, J. (1997) Metabotropic glutamate receptors in the rat nucleus accumbens. Eur. J. Neurosci. 9, 1514-1523.
127. Mark, R. J., Lovell, M. A., Markesbery, W. R., Uchida, K. and Mattson, M. P. (1997) A role for 4-hydroxynonenal, an aldehyde product of lipid peroxidation, in disruption of ion homeostatis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68, 255-264.
128. Martin, L. J., Blackstone, C. D., Huganir, R. L. and Price, D. L. (1992) Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 9, 259-270.
129. Mattson, R. (1997) Mother's legacy: Mitochondrial DNA mutations and Alzheimer's disease. Trends Neurosci. 20, 373-375.
130. Mayeux, R., Saunders, A. N., Shea, S. et al. (1998) Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. New Engl. J. Med. 338, 506-511.
131. McConnell, L. M., Koenig, B. A., Greely, H. T., Raffin, T. A. and The Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics & Society. (1998) Genetic testing and Alzheimer disease: Has the time come? Nature Med. 4, 757-759.
132. McDonald, J. W., Althomsons, S. P., Hyrc, K. L., Choi, D. W. and Goldberg, M. P. (1998) Oligodendrocytes from forebrain are highly vulnerable to AMPA/ kainate receptor-mediated excitotoxicity. Nature Med. 4, 291-297.
133. McGeer, P. L. and McGeer, E. G. (1995) The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21, 195-218.
134. Meltzer, L. T., Christoffersen, C. L. and Serpa, K. A. (1997) Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci. Biohehav. Rev. 21, 511-518.
135. Merrill, J. E. and Benveniste, E. N. (1996) Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosei. 19, 331-338.
136. Miyakawa, T., Yagi, T., Kitazawa, H. et al. (1997) Fynkinase as a determinant of ethanol sensitivity: Relation to NMDA-receptor function. Science 278, 698-701.
137. Miyata, M. and Smith, J. D. (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nature Gent 14, 55-60.
138. Monaghan, D. T., Bridges, R. J. and Cotman, C. W. (1989) The excitatory amino acid receptors: Their classes, pharmacology, and distinct properties in the function of the central nervous system. Ann. Rev. Pharmacol. Toxicol. 29, 365-402.
139. Morari, M., Sbrenna, S., Marti, M. et al. (1998) Evidence for striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat. Eur. J. Neurosci. 10, 1716-1722.
140. Morelli, M. (1997) Dopamine/glutamate interaction as studied by combining turning behaviour and c-fos expression. Neurosci. Biobehav. Rev. 21, 505-510.
141. Moriyoshi, K., Masu, M., Ishii, T., Shigemoto, R., Mizuno, N. and Nakanishi, S. (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354, 31-37.
142. Morrison, J. H., Siegel, S. J., Gazzaley, A. H. and Huntley, G. W. (1996) Glutamate receptors: Emerging links between subunit proteins and specific excitatory circuits in primate hippocampus and neocortex. Neuroscientist 2, 272-283.
143. Mullan, M., Crawford, F. and Buchanan, J. (1994) Technical feasibility of genetic testing for Alzheimer's disease. Alz. Dis. Assoc. Disord. 8, 102-115.
144. Müller, W. E., Mutschler, E. and Riederer, P. (1995) Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiat. 28, 113-124.
145. 1B receptors. Eur. J. Neurosci. 10, 2371-2379.
146. Murgolo, N. J., Brown, J. E., Bayne, M. L. and Strader, C. D. (1996) Presenilin mutations in Alzheimer's disease: Molecular models suggest a potential functional locus. Trends Pharmacol. Sci. 17, 389-393.
147. Nankai, M., Klarica, M., Fage, D. and Carter, C. (1998) The pharmacology of native N-methyl-D-aspartate receptor subtypes: Different receptors control the release of different striatal and spinal transmitter. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 22, 35-64.
148. Naranjo, J. R., Mellström, B., Carrión, A. M., Lucas, J. J., Foulkes, N. S. and Sassone-Corsi, P. (1997) Peripheral noxious stimulation induces CREM expression in dorsal horn: Involvement of glutamate. Eur. J. Neurosci. 9, 2778-2783.
149. National Institute of Aging/Alzheimer's Association Working Group (1996) Apolipoprotein E genotyping in Alzheimer's disease. Lancet 347, 1091-1095.
150. Nayak, A., Zastrow, D. J., Lickteig, R., Zahniser, N. R. and Browning, M. D. (1998) Maintenance of late-phase LTP is accompanied by PKA-dependent increase in AMPA receptor synthesis. Nature 394, 680-683.
151. Neve, R. L. and Robakis, N. K. (1998) Alzheimer's disease: A re-examination of the amyloid hypothesis. Trends Neurosci. 21, 15-19.
152. Nicholson, D. W. and Thornberry, N. A. (1997) Caspases: Killer proteases. Trends Biochem. Sci. 22, 299-306.
153. Nicoletti, E., Bruno, V., Copani, A., Casabona, G. and Knöpfel, T. (1996) Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders? Trends Neurosci. 19, 267-271.
154. Novikova, L., Novikov, L. and Kellerth, J.-O. (1997) Effects of neurotransplants and BDNF on the survival and regeneration of injured adult spinal motoneurons. Eur. J. Neurosci. 9, 2774-2777.
155. Okabe, S., Vicario-Abejón, C., Segal, M. and McKay, R. D. G. (1998) Survival and synaptogenesis of hippocampal neurons without NMDA receptor function in culture. Eur. J. Neurosci. 10, 2192-2198.
156. O'Keefe, J. and Dostrovsky, J. (1971) The hippocampus as a spatial map. Preliminary evidence from unit activity in the freely moving rat. Brain Res. 34, 171-175.
157. Okuizumi, K., Onodera, O., Tanaka, H. et al. (1994) ApoE-ε4 and early-onset Alzheimer's. Nature Genet. 7, 10-11.
158. Olney, J. W., Labruyere, J. and Price, M. T. (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244, 1360-1362.
159. Olson, L. (1997) Regeneration in the adult central nervous system: Experimental repair strategies. Nature Med. 3, 1329-1335.
160. Ott, A., Breteler, M. M. B., van Harskamp, F., Grobbee, D. E. and Hofman, A. (1997) The incidence of dementia in the Rotterdam study. In Alzheimer's Disease: Biology, Diagnosis and Therapeutics. (K. Iqbal, B. Winblad, T. Nishimura, M. Takeda and H. M. Wisniewski, Eds). Wiley, Chichester, pp. 3-10.
161. Otterson, O. P. and Landsend, A. S. (1997) Organization of glutamate receptors at the synapse. Eur. J. Neurosci. 9, 2219-2224.
162. Paas, Y. (1998) The macro-and microarchitectures of the ligand-binding domain of glutamate receptors. Trends Neurosci. 21, 117-125.
163. Pan, W., Zadana, J. E., Harlan, R. E., Weber, J. T., Banks, W. A. and Kastin, A. J. (1997) Tumor necrosis factor-α: A neuromodulator in the CNS. Neurosci. Behav. Rev. 21, 603-613.
164. Pantey, M., Ritter, R. and Görtelmeyer, R. (1993) Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Zeitschr. Gerontopsychol. Psychiat. 6, 103-117.
165. Paolillo, M., Montecucco, A., Zanassi, P. and Schinelli, S. (1998) Potentiation of dopamine-induced cAMP formation by group I metabotropic glutamate receptors via protein kinase C in cultured striatal neurons. Eur. J. Neurosci. 10, 1937-1945.
166. Parpura-Gill, A., Beitz, D. and Uemura, E. (1997) The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain Res. 754, 65-71.
167. Parsons, C. G., Gruner, R., Rozental, J., Millar, J. and Lodge, D. (1993) Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacol. 32, 1337-1350.
168. Parsons, C. G., Panchenko, V. A., Pinchenko, V. O., Tsydrenko, A. Y. and Krishtal, O. A. (1996) Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur. J. Neurosci. 8, 446-454.
169. 2+-permeable AMPA receptors in neurological disorders. Trends Neurosci. 20, 464-470.
170. Pericak-Vance, M. A., Bass, M. P., Yamaoka, L. H. et al. (1997) Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 278, 1237-1241.
171. Pines, G., Danbolt, N. C., Bjoras, M. et al. (1992) Cloning and expression of a rat brain L-glutamate transporter. Nature 360, 464-467.
172. Pirttilä, T., Soininen, H., Mehta, P. D. et al. (1996) Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. Neurobiol. Aging 18, 121-127.
173. Reiman, E. M., Caselli, R. J., Yun, L. S. et al. (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. New Engl. J. Med. 334, 752-758.
174. Ridet, J. L., Malhotra, S. K., Privat, A. and Gage, F. H. (1997) Reactive astrocytes: Cellular and molecular cues to biological function. Trends Neurosci. 20, 570-577.
175. Riedel, G. (1996) Function of metabotropic glutamate receptors in learning and memory. Trends Neurosci. 19, 219-224.
176. Riedel, G., Wetzel, W. and Reymann, K. G. (1996) Comparing the role of metabotropic glutamate receptors in long-term potentiation and in learning and memory. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 20, 761-789.
177. Rosenmund, C., Stern-Bach, Y. and Stevens, C. F. (1998) The tetrameric structure of a glutamate receptor channel. Science 280, 1596-1599.
178. Roses, A. D. and Saunders, A. M. (1997) Apolipoprotein E genotyping as a
179. Roses, A. D., Strittmatter, W. J., Pericak-Vance, A., Corder. E. H., Saunders, A. M. and Schmechel, D. E. (1994) Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet 343, 1564-1565.
180. Rüther, E. and Glasser, A. (1988) The NMDA-antagonist memantine in severe dementia: Results of a prospective postmarketing surveillance study. Neurobiol. Aging 19/4S, S760.
181. Sánchez-Prieto, J., Budd, D. C., Herrero, I., Vázquez, E. and Nichols, D. G. (1996) Presynaptic receptors and the control of glutamate exocytosis. Trends Neurosci. 19, 235-239.
182. Saunders, A. M., Hulette, C., Welsh-Bohmer, K. A. et al. (1996) Specificity, sensitivity, and predictive value of apolipoprotein E genotyping for sporadic Alzheimer's disease. Lancet 348, 90-93.
183. Schächter, F., Faure-Delanef, L., Guénot, F. et al. (1994) Genetic associations with human longevity at the APOE and ACE loci. Nature Genet. 6, 29-32.
184. Schmidt, W. J. and Kretschmer, B. D. (1997) Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci. Biobehav. Rev. 21, 381-392.
185. Schoepp, D. D. and Conn, P. J. (1993) Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol. Sci. 14, 13-20.
186. Schultz, H., Jobert, M., Coppola, R., Herrmann, W. M. and Pantev, M. (1996) The use of diurnal vigilance changes in the EEG to verify vigilance-enhancing effects of memantine in a clinical pharmacological study. Neuropsychobiology 33, 32-40.
187. Selkoe, D. (1997) Alzheimer's disease: Genotypes, phenotype, and treatments. Science 275, 630-631.
188. Sengpiel, B., Preis, E., Krieglstein, J. and Prehn, J. H. M. (1998) NMDA-induced superoxide production and neurotoxicity in cultured rat hippocampal neurons: Role of mitochondria. Eur. J. Neurosci. 10, 1903-1910.
189. Sheng, M. (1997) Glutamate receptors put in their place. Nature 386, 221-222.
190. Skoog, I., Nilsson, L., Palmertz, B., Andreasson, L.-A. and Svanborg, A. (1993) A population-based study of dementia in 85-year-olds. New Engl. J. Med. 328, 153-158.
191. Spike. R. C., Kerr, R., Maxwell, D. J. and Todd, A. J. (1998) GluR1 and GluR2/3 subunits of the AMPA-type glutamate receptor are associated with particular types of neurone in laminae I-III of the spinal dorsal horn of the rat. Eur. J. Neurosci. 10, 324-333.
192. Starr, M. S., Starr, B. S. and Kaur, S. (1997) Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Neurosci. Biobehav. Rev. 21, 437-446.
193. Steele, J. E., Palmer, A. M., Stratmann, G. C. and Bowen, D. M. (1989) The N-methyl-D-aspartate receptor complex in Alzheimer's disease: Reduced regulation by glycine but not zinc. Brain Res. 500, 369-373.
194. Steinhäuser, C. and Gallo, V. (1996) News on glutamate receptors in glial cells. Trends Neurosci. 19, 339-345.
195. Stewart, G. R., Zorumski, C. F., Price, M. T. and Olney, J. T. (1990) Domoic acid: A dementia-inducing excitotoxic food poison with kainic acid receptor specificity. Exp. Neurol. 110, 127-138.
196. +-dependent glutamate/aspartate transporter from rat brain. Proc. Nat. Acad. Sci. USA 89, 10955-10959.
197. Sucher, N. J., Awobuluyi, M., Choi, Y.-B. and Lipton, S. A. (1996) NMDA receptors: From genes to channels. Trends Pharmacol. Sci. 17, 348-355.
198. Tanzi, R. E. (1998) The role of presenilins, apoptosis and Aβ in the etiology of AD. Neurobiol. Aging 19/4S, S306.
199. Thal, E. J., Carta, A., Doody, R., Leber, P., Mohs, R., Schneider, E.. Shimohama, S. and Silber, C. (1997) Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alz. Dis. Assoc. Disord. 11, Suppl. 3, 46-49.
200. Trotti, D., Nussberger, S., Volterra, A. and Hediger, M. A. (1997) Differential modulation of the uptake currents by redoc interconversion of cysteine residues in the human neuronal glutamate transporter EAAC1. Eur. J. Neurosci. 9, 2207-2212.
201. Tsai, G. E., Ragan, P., Chang, R., Chen, S., Linnoila, M. I. and Coyle, J. T. (1998) Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am. J. Psychiat. 155, 726-732.
202. Uberti, D., Rizzini, C., Galli, P. et al. (1997) Priming of cultured neurons with sabeluzole results in long-lasting inhibition of neurotoxin-induced tau expression and cell death. Synapse 26, 95-103.
203. Uberti, D., Belloni, M., Grilli, M., Spano, P. and Memo, M. (1998) Induction of tumour-suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurons triggered by excitatory amino acids. Eur. J. Neurosci. 10, 246-254.
204. Ullensvang, K., Lehre, K. P., Storm-Mathisen, J. and Danbolt, N. C. (1997) Differential developmental expression of the two rat brain glutamate transporter proteins GLAST and GLT. Eur. J. Neurosci. 9, 1646-1655.
205. van Duijn, C. M., de Knijff, P., Cruts, M., Wehnert, A., Havekes, L. M., Hofman, A. and van Broeckhoven, C. (1994) Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nature Genet. 7, 74-78.
206. Vázquez, E. and Sánchez-Prieto, J. (1997) Presynaptic modulation of glutamate release targets different calcium channels in rat cerebrocortical nerve terminals. Eur. J. Neurosci. 9, 2009-2018.
207. Verkhratsky, A. and Kettenmann, H. (1996) Calcium signalling in glial cells. Trends Neurosci. 19, 346-352.
208. Verkhratsky, A. and Toescu, E. C. (1998) Calcium and neuronal ageing. Trends Neurosci. 21, 2-7.
209. Wang, Y., Small, D. L., Stanimirovic, D. B., Morley, P. and Durkin, J. P. (1997) AMPA receptor-mediated regulation of a Gi-protein in cortical neurons. Nature 389, 502-504.
210. Watase, K., Hashimoto, K., Kano, M. et al. (1998) Motor discoordination and increased susceptibility to cerebellar injury in GLAST mutant mice. Eur. J. Neurosci. 10, 976-988.
211. Watkins, J. C. and Olverman, H. J. (1987) Agonists and antagonists for excitatory amino acid receptors. Trends Neurosci. 10, 265-272.
212. Whitton, P. S. (1997) Glutaminergic control over brain dopamine release in vivo and in vitro. Neurosci. Biobehav. Rev. 21, 481-488.
213. Wigström, H. and Gustafsson, B. (1986) Postsynaptic control of hippocampal long-term potentiation. J. Physiol. (Paris) 81, 228-236.
214. Wimo, A., Erikson, T., Mattsson, B., Krakau, I., Nelvig, A. and Karlsson, G. (1995) Cost-utility analysis of group living in dementia care. Int. J. Tech. Assoc. Health Care 11, 49-65.
215. Wimo, A., Mattsson, B., Krakau, I., Eriksson, T. and Nelvig, A. (1994) Cost-effective analysis of dementia day care - a controlled Swedish study. Health Economics 3, 395-404.
216. Wimo, A., Karlsson, G., Sandman, P. O., Corder, L. and Winblad, B. (1997a) Cost of illness due to dementia in Sweden. Int. J. Geriatr. Psychiat. 12, 857-861.
217. Wimo, A., Ljunggren, G. and Winblad, B. (1997b) Costs of dementia and dementia care - a review. Int. J. Geriatr. Psychiat. 12, 841-856.
218. Wimo, A., Karlsson, G., Nordberg, A. and Winblad, B. (1997c) Treatment of Alzheimer disease with tacrine: A cost-analysis model. Alz. Dis. Assoc. Disord. 11, 191-200.
219. Winblad, B., Ljunggren, G., Karlsson, G. and Wimo, A. (1996) What are the costs to society and to individuals regarding diagnostic procedures and care of patients with dementia? Acta Neurol. Scand., Suppl. 168, 101-104.
220. Winblad, B., Hill, S., Beermann, B., Post, S. G. and Wimo, A. (1997a) Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines Alz. Dis. Assoc. Disord. 11, Suppl. 3, 39-45.
221. Winblad, B., Corder, E., Fratiglioni, L., Basun, H., Lannfelt, L. and Viitanen, M. (1997b) The prevalence of clinical dementia diagnosis varies with apolipoprotein E polymorphism in a population sample of very old adults. In Alzheimer's Disease: Biology, Diagnosis and Therapeutics (K. Iqbal, B. Winblad, T. Nishimura, M. Takeda and H. M. Wisniewski, Eds). Wiley, Chichester, pp. 39-44.
222. Winblad, B. and Poritis, N. (1998) Clinical improvement in a placebo-controlled trial with memantine in care-dependent patients with severe dementia. Neurobiol. Aging 19/4S, S1267.
223. Wong, P. C., Zheng, H., Chen. H. et al. (1997) Presenilin 1 is required for Notch 1 and DII1 expression in the paraxial mesoderm. Nature 387, 288-292.
224. Wragg, M., Hutton, M., Talbot, C. and the Alzheimer's Disease Collaborative Group (1996) Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Lancet 347, 509-512.
225. Yan, S. D., Chen, X., Fu, J. et al. (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691.
226. Zajaczkowski, W. and Danysz, W. (1997) Effects of D-cycloserine and aniracetam on spatial learning in rats with entorhinal cortex lesions. Pharmacol. Biochem. Behav. 56, 21-29.
227. Zajaczkowski, W., Frankiewicz, T., Parsons, C. G. and Danysz, W. (1997) Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacol. 36, 961-971.
228. Zayed, H. and Manning, S. (1995) Primary care. A profile of the major European markets. Financial Times. Pharmaceuticals & Healthcare Publishing, London.